Format

Send to

Choose Destination
Cell Stem Cell. 2015 Jan 8;16(1):13-7. doi: 10.1016/j.stem.2014.12.013.

Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies.

Author information

1
Department of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
2
Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
3
The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK.
4
TAP Biosystems, Royston, Hertfordshire, SG8 5WY, UK.
5
The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, OX3 7LD, UK.
6
Centre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, LE11 3TU, UK.
7
Department of Nanobiomedical Science and BK21 Plus NBM Global Research Center of Regenerative Medicine, Dankook University, Cheonan 330-714, Republic of Korea; Institute of Tissue Regeneration Engineering, Dankook University Graduate School, Cheonan 330-714, Republic of Korea; Department of Dental Biomaterials, School of Dentistry, Dankook University, Shinbu-dong, Cheonan 330-714, Republic of Korea.
8
Ocular Biology and Therapeutics, Institute of Ophthalmology, University College London, London, EC1V 9EL, UK; Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-5060, USA.
9
Australian Institute for Bioengineering & Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia; School of Chemical Engineering, The University of Queensland, St. Lucia, QLD 4072, Australia; Materials Science and Engineering Division, CSIRO, Clayton, VIC 3169, Australia.
10
New York Stem Cell Foundation, New York, NY 10023, USA.
11
Burnham Medical Research Institute, La Jolla, CA 92037, USA; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92161, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
12
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.
13
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK.
14
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, OX3 7LD, UK; Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London WC1H 9JP, UK.
15
Department of Biochemical Engineering, University College London, London, WC1H 0AH, UK; Department of Nanobiomedical Science and BK21 Plus NBM Global Research Center of Regenerative Medicine, Dankook University, Cheonan 330-714, Republic of Korea; Institute of Tissue Regeneration Engineering, Dankook University Graduate School, Cheonan 330-714, Republic of Korea. Electronic address: i.wall@ucl.ac.uk.

Abstract

Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.

PMID:
25575079
DOI:
10.1016/j.stem.2014.12.013
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center